Labopharm to be acquired by Paladin Labs

Labopharm (NASDAQ:DDSS; TSX:DDS) has accepted a takeover bid from Paladin Labs (TSX:PLB), which will make an offer for all of the common shares of Labopharm at a price of 28.57 cents a share in cash. The purchase price represents a premium of 57.4% over the volume-weighted average price of Labopharm’s shares of 18.15 cents for the 30 trading [...]

Labopharm partner loses tramadol patent appeal

The U.S. Court of Appeals for the Federal Circuit has ruled that Purdue Pharma Products’ patent claims for controlled-release tramadol, a pain medication, are invalid.  Purdue distributes Labopharm’s (TSX:DDS; NASDAQ:DDSS) tramadol drug Ryzolt in the U.S. Generic drug maker Par Pharmaceutical (NYSE:PRX) had argued that the patent claims should be deemed invalid because they were [...]

Analysts cut Labopharm price targets on marketing deal

After weighing the pros and cons of Labopharm’s joint venture marketing accord with Italy’s Gruppo Angelini, Dundee Securities and Versant Partners cut their price targets on “buy-rated” Labopharm (TSX: DDS; NASDAQ: DDSS), with Dundee moving the target down to $2.40 from $3 and Versant down to $2.50 from $3. Dundee analyst David Martin cited “increased [...]

Yorkville in financing pact with Allon

YA Global Master SPV, a fund managed by Yorkville Advisors LLC, has made its third standby equity distribution agreement in the Canadian biotech sector in recent months, agreeing to provide up to $10 million of capital to Allon Therapeutics (TSX:NPC) over the next three years at Allon’s discretion. “We are enthusiastic about our investment in [...]

Labopharm closes public offering of units

Labopharm (TSX:DDS; NASDAQ:DDSS) has closed a public offering of 11,764,706 units priced at $1.70 (U.S.) a unit for net proceeds of $18.15 million, after deducting underwriting and estimated offering expenses. Each unit consists of one common share and a warrant to purchase 0.5 of a common share.  Each warrant entitles the holder to acquire one [...]

Labopharm’s new antidepressant to be ‘game-changer’

It’s game on for Labopharm (TSX:DDS; NASDAQ:DDSS). By February 11, the FDA is expected to approve the company’s antidepressant trazodone, a novel once-daily formulation that addresses many of the shortcomings of similar drugs on the market.  “I think it’s fair to say this drug could be a game-changer for us,” CEO James Howard-Tripp says in [...]

Labopharm’s trazodone drug in peer-reviewed medical journal

An article in the October issue of CNS Spectrums, an international journal of neuropsychiatric medicine, cites the potential benefits of Labopharm’s new trazodone formulation, which contains its Contramid technology to control the release of active ingredients to improve drug delivery. “Although trazodone has traditionally been used as a low dose hypnotic, a new controlled release [...]